New insights on a common protein could lead to novel cancer treatments

November 04, 2020

A new University of Colorado Boulder-led study sheds light on a protein key to controlling how cells grow, proliferate and function and long implicated in tumor development.

The findings, published this week in the journal Genes and Development, could lead not only to new therapies for hard-to-treat cancers, but also inform novel treatments for neurological diseases and rare developmental disorders, the authors say.

"These findings could have broad biomedical application," said lead author Dylan Taatjes, a professor in the Department of Biochemistry.

For decades, scientists have known that the protein Cyclin Dependent Kinase 7 (CDK7) plays an instrumental role in helping all cell types transcribe, or decode, the genetic instructions provided by their DNA.

As Taatjes explains, each cell contains the same vast library, or genome. But a kidney cell may turn to different sections of that library for instructions than, say, a skin cell or a heart cell. Like a librarian, CDK7 helps ensure that each cell accesses the right instructions at the right time, guiding which genes get flipped on and off.

While that's important during human development and for normal cell function, CDK7 can be exploited by cancer cells to drive runaway growth. In recent years, scientists have discovered that the protein can fuel certain cancers to proliferate out of control, including "triple negative" breast cancers, which are more aggressive and don't respond well to common treatments.

That finding has inspired growing interest in the development of so-called "CDK7-inhibitors" but due to a lack of understanding of what the CDK7 does, early clinical trials have been disappointing.

"We wanted to find out exactly how it's really working inside human cells," Taatjes said.

To that end, the Taatjes lab teamed up with scientists from two pharmaceutical companies, Syros and Paraza, as well as colleagues in other CU Boulder labs, the University of Colorado School of Medicine and the BioFrontiers Institute.

Using sophisticated analytical techniques, basic biochemistry and next-generation genetic sequencing, the team identified, for the first time, the hundreds of specific proteins that CDK7 switches on or off, providing unprecedented insight into its role in cells.

The study also revealed that:Phase 1 trials are currently underway administering the latest version of CDK7 inhibitors to drug-resistant breast, colorectal, lung, ovarian and pancreatic cancer patients.

The findings of the new study suggest such drugs hold promise, Taatjes said.

"In biology, it is widely recognized that cells will compensate by activating other enzymes if one specific enzyme is inhibited," he said, explaining the mechanism behind drug resistance. "Our results suggest that CDK7 inhibitors could have distinct therapeutic advantages, given that they would not only block CDK7, but would impact the function of other enzymes."

The research could also lead to next-generation therapeutics, which--instead of silencing the protein completely--would target it only in its liberated, most active phase. This could result in more selective inhibitors that would be less damaging to healthy cells, with fewer side effects.

And because of its many roles in shaping how human cells develop and function, other applications may be possible.

"Cancer is an obvious application but it is by no means the only one," Taatjes said.
-end-


University of Colorado at Boulder

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.